BFC Planning’s Travere Therapeutics TVTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.65K Buy
79
+12
+18% +$733 ﹤0.01% 2718
2026
Q2
$3.81K Hold
67
– – ﹤0.01% 2776
2026
Q1
$1.99K Sell
67
-2
-3% -$60 ﹤0.01% 2598
2025
Q4
$2.64K Buy
+69
New +$2.24K ﹤0.01% 2554

Other funds holding TVTX

BFC Planning's TVTX Position: Q3 2026 in Review

BFC Planning increased its Travere Therapeutics (TVTX) stake by 18% in Q3 2026, buying an estimated $733 and bringing the position to 79 shares worth $4.65K. The position accounts for ﹤0.01% of the portfolio, ranked #2718.

BFC Planning first reported a position in TVTX in Q4 2025 and has held it in 4 quarters since. 254 funds tracked by Wall St. Rank hold TVTX as of Q3 2026.

  • BFC Planning held 79 shares of Travere Therapeutics worth $4.65K as of Q3 2026.
  • BFC Planning bought 12 Travere Therapeutics shares in Q3 2026, an estimated $733.
  • Travere Therapeutics made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #2718 holding.
  • BFC Planning first reported a position in Travere Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • 254 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.